Introduction
Skin wound healing is a complex process involving collaborative efforts of multiple cell types, newly synthesized extracellular matrices and growth factors. Inflammation, reepithelialization, granulation tissue formation and remodeling are the proposed sequential events during skin wound healing under physiological conditions (Martin, 1997; Singer and Clark, 1999) . Abnormalities in any of the events could result in either delayed wound healing or a wound healed with hypertrophic scars (Tredget et al., 1997) . Throughout the wound healing process, cell migration is a rate-limiting event. The epidermal keratinocytes laterally migrate across the wound bed to resurface the wound, the process known as wound reepithelialization. The dermal fibroblasts move into the wound to produce and deposit new matrix proteins. Finally, the dermal microvascular endothelial cells that have entered the wounded tissue are responsible for building new blood vessels. It has long been recognized that epidermal and dermal cells do not enter the wound bed at the same time. Following wounding, keratinocyte migration occurs within hours, whereas migration of the dermal cells remains undetectable until several days later (Singer and Clark, 1999) . These observations are in accordance with the notion that wound closure by keratinocyte migration precedes wound remodeling by the dermal cells (Clark, 1993; Falanga, 2004) . However, the regulation of the sequential epidermal and dermal cell migration remained a mystery.
In intact skin, cells are bathed in interstitial fluid, largely a filtrate of plasma in blood vessels. When skin is wounded, the cells at the cut edge of the wound experience a dramatic microenvironmental transition from plasma to a new environment of serum for the first time (Henry et al., 2003) . Bandyopadhyay and colleagues discovered a key factor in human serum, TGFb3 that seems to play the ''traffic control'' role in migration of epidermal versus dermal cells. They showed that human serum selectively inhibits the migration of dermal fibroblasts and microvascular endothelial cells via TGFb3 (not TGFb1 or TGFb2). Furthermore, they demonstrated that the differential responses of keratinocytes versus dermal fibroblasts to TGFb3's anti-motility signal are due to the difference in the expression levels of type II TGFb receptor (TbRII) in these cells (Bandyopadhyay et al., 2006) . Therefore, this finding suggests that it is TGFb3 in human serum that selectively halts dermal cell migration for a few days, allowing keratinocyte migration take place under the microenvironment of serum.
The three mammalian TGFb members, TGFb1, TGFb2 and TGFb3, bind to and transmit signals via the common heterodimeric complex of TbRII and TbRI serine/threonine kinases (Wrana et al., 1992; Attisano and Wrana, 1996; Piek et al., 1999; Miyazono, 2000; Derynck and Zhang, 2003; Shi and Massagué, 2003) . In this classical model, TGFb binds to TbRII, which in turn recruits, transphosphorylates and activates TbRI (Derynck and Feng, 1997; Shi and Massagué, 2003) . The activated TbRII/TbRI complex then engages R-Smaddependent and/or R-Smad-independent signaling pathways inside the cells (Miyazono, 2000; Mulder, 2000; Derynck and Zhang, 2003; Moustakas and Heldin, 2005) . However, several recent studies started challenging the dogma of TbRII/TbRI signaling and suggested that TbRII and TbRI are not always required to work together to mediate TGFb signaling. An earlier study by Zhang and colleagues provided biochemical support that TbRII under physiological expression levels are able to form homodimers in response to TGFb stimulation (Zhang et al., 2009) . Bandyopadhyay et al. showed that TbRII alone is able to mediate TGFb signaling to ERK 1/2 , in the absence of TbRI and TbRIII in primary human dermal fibroblasts (Bandyopadhyay et al., 2011) . Moreover, Iwata et al. have recently reported that TbRI and TbRIII are able to mediate TGFb signaling to TRAF6/ TAK1/p38 pathway in TbRII 2/2 mouse cranial neural crest cells (Iwata et al., 2012 ).
In the current study, we undertook a systematic approach to identify the pathway through which the anti-motility signal of TGFb3 travels in primary human dermal fibroblasts. While our results demonstrated the necessity for the conventional TbRII/ TbRI and Smad2/3/4 complexes, they also revealed a detour of the post-Smad signaling to the PKA . CREB pathway for the anti-motility signal. This is the first report on ''anti-motility signaling pathway'' for the TGFb family cytokines.
Results

Profiles of TGFb family cytokines in normal human skin
TGFb in skin can come from two sources, filtrate of blood circulation and secretion by the skin cells. It is technically difficult to establish TGFb profiles in unwounded intact skin, since human skin isolated by biopsy is in fact ''wounded'' tissue. In wounded tissues, the main source for TGFb1 comes from degranulation of the platelets, in which TGFb1 is the only isoform present in the a-granules (Assoian et al., 1983; Roberts and Sporn, 1996) . The source for TGFb2 and TGFb3 remains largely unknown. There have been reports that human serum, but not plasma, contains active TGFb3 at a concentration range of 1-2 ng/ml (Hering et al., 2001) , in comparison to 10-50 ng/ml of TGFb1 in human serum (Assoian et al., 1983; Roberts and Sporn, 1996; Grainger et al., 2000) . Since the half-life of TGFb is short (2-3 minutes), the majority of TGFb isoforms in serum must be in complexes with carrier proteins, such as latency-associated peptide (LAP) and latent TGFb1-binding protein (LTBP) (Roberts, 1998) . These TGFb-bound carrier proteins can be cleaved in serum and new TGFb is made available (Roberts, 1998; Khalil, 1999; Murphy-Ullrich and Poczatek, 2000) . Based on the above understanding, we examined the profiles of the three TGFb family members using frozen section of normal adult human skin. As shown in Fig. 1 , anti-TGFb1 antibody stained the dermis of the skin significantly stronger than the epidermis (panel B versus panel A). As expected, anti-TGFb2 antibody (panel D) and anti-TGFb3 antibody (panel F) staining of the skin sections was much weaker than anti-TGFb1 antibody staining. These data indicate that human skin contains mainly TGFb1 and lower levels of TGFb2 and TGFb3, provided that the three antibodies share similar affinity toward their antigens. To test whether or not the weaker staining by anti-TGFb3 antibody was due to its lower affinity toward TGFb3, we incubated the skin sections with human recombinant TGFb3 prior to anti-TGFb3 antibody staining. We detected a strong and almost exclusively staining of the dermis (panel H). These results indicated that 1) the weaker staining of the skin sections by anti-TGFb3 antibody (panel F) was not due to a compromise in the antibody's affinity for TGFb3 and 2) dermal cells are the primary targets for environmental TGFb3, consistent with our previous finding that human dermal cells express 7-15 fold higher levels of TbRII than human keratinocytes (Bandyopadhyay et al., 2006) .
Human dermal fibroblasts provide a unique cell model to define anti-motility signaling of TGFb3
Migration of human keratinocytes (HKCs) and human dermal fibroblasts (HDFs) into the wound are two critical events during wound healing. However, a major difference between these two cell types lies in distinct responses of these cells to the antimotility signal of TGFb3, (Bandyopadhyay et al., 2006) . As shown in Fig. 2 , in the absence of TGFb3, HDF stimulus, PDGFbb (A), and HKC stimulus, TGFa (B), strongly stimulated . Migration Index (MI) was used to quantitate cell migration. Under similar conditions, both PDGFbb (C) and TGFa (D) also stimulated DNA synthesis in HDFs and HKCs (bars 2 versus bars 1). Interestingly, in contrast to the selective inhibition of HDF migration by TGFb3, TGFb3 inhibited growth factor-induced DNA synthesis in both HDFs and HKCs in a dose-dependent manner (bars 3-7 versus bars 2). These data suggest that the TGFb receptors in HDFs allows both anti-proliferation and anti-motility signals of TGFb3 to enter the cells, whereas the TGFb receptors in HKCs only transmit the anti-proliferation, but not anti-motility, signal of TGFb3. Therefore, comparative studies between HDFs and HKCs would provide a unique model system for defining the signaling pathway by which TGFb3 blocks growth factor-stimulated cell migration -the anti-motility signaling mechanism by TGFb3.
TbRII transmits the anti-motility signal of TGFb3 in full to TbRI/Alk5
We have previously shown that it is the higher expression level of TbRII in HDFs (than in HKCs) that makes HDFs sensitive to the anti-motility signal of TGFb3 (Bandyopadhyay et al., 2006) . Therefore, we chose TbRII as the starting signaling molecule. We asked whether TbRII transmits the anti-motility signal of TGFb3 to TbRI or independent of TbRI. We used the lentiviral shRNAdelivery system, FG12 (Qin et al., 2003) , to downregulate the endogenous TbRI in HDFs. The FG12 system, as shown in Fig. 3A , offers more than 90% transduction efficiency in HDFs as indicated by a green fluorescent protein (GFP) gene expression by the vector following a single infection. Downregulation of TbRI by one of the shRNAs (shTbRI-NO. 2) is shown in Fig. 3B (panel a, lane 2 versus lane 1). In these cells, we observed that TGFb3-stimulated phosphorylation of Smad3 became undetectable, while the levels of TbRII remained unaffected (Bandyopadhyay et al., 2011) . When these cells were subjected to the colloidal gold migration assay, as shown in Fig. 3C , TGFb3 was no longer able to block PDGF-bb-stimulated migration of the TbRI-downregulated cells (bar 6) in comparison to the parental HDFs (bar 3). These results indicated that the endogenous TbRI is required for transmitting the anti-motility signal of TGFb3.
We then tested whether TbRII transmits the anti-motility signal of TGFb3 in full to TbRI, i.e. whether activation of TbRI alone is sufficient to replace TGFb3. We took an advantage of the constitutively activated mutant of TbRI, the TbRI-TD mutant (Wieser et al., 1995) . We reasoned that if expression of TbRI-TD alone were able to block PDGF-bb-stimulated migration even in the absence of TGFb3, it indicates that TbRII does not need any TbRI-independent pathways for transmitting the anti-motility signal of TGFb3. As shown in Fig. 3D , TbRI-wt (lane 2) and the TbRI-TD mutant (lane 3) genes were expressed several fold over the endogenous TbRI in HDFs by the lentiviral vector, pRRLSin (lane 1). The constitutive kinase activity of TbRI-TD was indicated by constitutive Smad3 phosphorylation even in the absence of TGFb3 under serum-free conditions (Fig. 3E , panel c, lane 1 versus lanes 2, 3, 4). In TbRI-wt-expressing HDFs, however, phosphorylation of Smad3 still depended upon TGFb3-stimulation (panel a, lanes 2, 3, 4 versus lane 1). Interestingly, the constitutively activated TbRI-Smad pathway was able to replace TGFb3's anti-motility signal. As shown in Fig. 3F , TbRI-TDexpressing HDFs failed to migrate in response to PDGF-bb stimulation even in the absence of TGFb3 (bar 5 versus bar 2). In contrast, the HDFs expressing TbRI-wt (inactive in the absence of TGFb3) behaved just like the parental HDFs, with a basal migration under serum-free conditions (bars 1), enhanced migration in response to PDGF-bb (bar 2) and inhibited migration in the presence of TGFb3 (bar 3).
Furthermore, we reasoned that if TbRI-TD was capable of carrying the full scale of the anti-motility signal of TGFb3, expression of TbRI-TD should be able to block migration of HKCs. As shown in supplementary material Fig. S1 , overexpression of TbRI-TD was sufficient to block TGFa-stimulated HKC migration even in the absence of TGFb3 (bars 5 versus bar 2). In comparison, TGFa-stimulated migration of HKCs expressing the TbRI-wt remained unaffected by TGFb3 (bar 3), just like the parental HKCs (Fig. 1) . Taken together, we The post-TbRII and TbRI signaling could use R-Smad-dependent or R-Smad-independent routes (Derynck and Zhang, 2003) . We first tested the R-Smad pathway. It is known that Smad2/3 are phosphorylated by activated TbRI and in turn form a complex with Smad4. This R-Smad trimeric complex translocates to the nucleus to regulate gene expression (Shi and Massagué, 2003) . To individually assess the three Smads, we designed two independent shRNAs against each Smad and introduced each of these shRNAs into HDFs by the FG-12 lentiviral shRNA system, as previously described. As shown in Fig. 4A , we achieved nearly complete downregulation of Smad 2 (panel a, lanes 1 and 2 versus lane 3), Smad 3 (panel c, lanes 1 and 2 versus lane 3), and partial downregulation of Smad4 (panel e, lanes 1 and 2 versus lane 3). The incomplete downregulation of Smad4 may reflect the fact that a fraction of Smad4 locates in the nucleus. These cells were then subjected to the colloidal gold migration assay. As shown in Fig. 3B , TGFb3 blocked PDGFbb-stimulated migration of HDFs infected with vector alone, as expected (bar 3 versus bar 2). However, downregulation of Smad2 prevented TGFb3 from inhibiting PDGF-bb-stimulated HDF migration (bar 6 versus bar 5). Similarly, downregulation of Smad3 also nullified TGFb3's anti-motility signaling (bar 9 versus bar 8). More intriguingly, even under partial downregulation of Smad4, TGFb3 was unable to inhibit PDGFbb-stimulated migration of the cells (bar 12 versus bar 11). Taken together, these data indicate that Smad2/3 in complex with Smad4 are required for transmitting the anti-motility signal from TGFb3.
After R-Smads, the anti-motility signaling of TGFb3 detours to PKA pathway
Where next does the R-Smad complex connect the anti-motility signal to? The possibilities include i) going into the nucleus to regulate expression of migration-suppressing genes or ii) connecting with other cytosolic signaling pathway(s). We preset two parameters to test these possibilities. First, we focused on primary targets of R-Smads, i.e. targets that are rapidly activated by TGFb3 in a R-Smad-dependent and protein synthesisindependent manner. Therefore, we chose 10 minutes (maximum phosphorylation of Smad2/3) as the stimulation time for TGFb3. Second, the to-be-identified new pathway should only be activated by TGFb3 in HDFs, but not in HKCs. Based on these parameters, we treated serum-starved HDFs and HKCs side-by-side with the same amount of TGFb3 for 10 minutes. Cell extracts were subjected to pathway screening with the Human Phospho-Kinase Antibody Array (ARY 003, R&D), which represents 46 well-characterized protein kinase pathways (supplementary material Fig. S2A ). As shown in Fig. 5B (HDFs) and Fig. 5C (HKCs) . In comparisons, we detected additional three pathways, b-catenin, p53 and eNOS, which were activated in both HDFs and HKCs in response to TGFb3 stimulation (dotted underlines, 1, 2 and 3). We decided to focus on PKA pathway for its possible role in mediating the antimotility signaling of TGFb3 for the following reasons. PKA has previously been shown as an antagonist of growth factor signaling (Cook and McCormick, 1993; Tokiwa et al., 1994) . In contrast, both ERK1/2 and Src are known downstream pathways of the PDGF-bb signaling and required for PDGF-bbstimulated cell proliferation and migration (Li et al., 2004a; Heldin and Westermark, 1996) . It is, therefore, less likely that these two pathways are simultaneously involved in the antimotility signaling of TGFb3. (F) The same cells were subjected to colloidal gold migration assays in response to PDGF-bb (15 ng/ml) in the absence or presence of TGFb3 (3 ng/ml). Migration Index (%) was shown. This experiment was repeated four times (n54, P#0.05). *Statistically significant over the control. (B) These individual Smad-downregulated HDFs were subjected to colloidal gold migration assays in response to PDGF-bb (15 ng/ml) in the absence or presence of TGFb3 (3 ng/ml). The migration was quantitated as Migration Index (%) (n53). *Statistically significant over the control, P,0.05. We directly confirmed that TGFb3 activates PKA pathway in HDFs, but not HKCs. Lysates of TGFb3-treated HDFs and HKCs were subjected to Western blot analysis with anti-phospho-CREB antibodies. As shown in Fig. 5D , TGFb3 stimulation clearly caused an increased CREB phosphorylation in HDFs (panel a, lane 2 versus lane 1), and this induction occurred in a time dependent manner (supplementary material Fig. S2B ). In contrast, a much weaker, if any, TGFb3-stimulated CREB phosphorylation was detected in HKCs (lanes 3 and 4) . This weaker induction was reproducible in time-course experiments (supplementary material Fig. S2B ). More importantly, we found that the TGFb3-stimulated CREB phosphorylation in HDFs depended upon the Smad pathway, since Smad4 downregulation prevented the TGFb3-stimulated CREB phosphorylation (Fig. 5E, panel a, lane 4 versus lane 2) . Phosphoimager scanning showed TGFb3-induced fold increases in CREB phosphorylation in HDFs versus HKCs. Therefore, PKA appeared to be a specific downstream effector of the Smads in HDFs in response to TGFb3.
PKA mediates anti-motility signaling of TGFb3
We undertook two complementary approaches to examine whether PKA acts downstream R-Smads to mediate TGFb3's anti-motility signal. First, we tested the effect of a chemical inhibitor, H-89, and a chemical activator, forskolin, of PKA pathway. As shown in Fig. 6A , PDGF-bb greatly enhanced HDF migration under serum-free conditions in the absence of TGFb3 (panel b versus panel a). The presence of TGFb3 completely nullified the stimulatory effect of PDGF-bb (panel c). However, in the presence of H89, TGFb3 was no longer able to block PDGF-bb-stimulated HDF migration (panel d versus panel c). Consistently, H89 inhibited TGFb3-induced phosphorylation of CREB (Fig. 6B, panel a, lane 3 versus lane 2) . In comparison, H89 did not affect TGFb3-stimulated phosphorylation of Smad3 in the same cells (panel b, lane 3 versus lane 2), consistent with the notion that R-Smads are upstream of PKA in response to TGFb3. Similarly, the PKA activator, forskolin, recapitulated the effect of TGFb3. As shown in Fig. 6C , the presence of forskolin caused increased phosphorylation of CREB under serum-free and TGFb3-free conditions (insert) and treatment with forskolin alone was able to block PDGF-bb-stimulated HDF migration in a dose-dependent manner (bars 3 to 7 versus bar 2).
Second, since few chemical inhibitors/activators could claim absolute specificity, we next directly targeted the catalytic subunit of human PKA, the PKA-Ca, with shRNA technology. We designed two shRNAs against the human PKA-Ca and individually delivered them by the FG-12 lentiviral system into HDFs. It is shown in Fig. 7A that PKA-Ca was clearly detected in FG-12 vector-infected HDFs (panel a, lane 1) . However, PKACa expression was dramatically downregulated in cells infected with shRNA-NO. 1 or shRNA-NO. 2 against PKA-Ca (panel a, lanes 2 and 3). The effect of PKA-Ca downregulation was also confirmed by blockade of forskolin-stimulated CREB phosphorylation in these cells (Fig. 7B, panel a, lane 4 versus  lane 2) . In contrast, in the same cells, TGFb3 was still able to induce Smad2/3 phosphorylation (Fig. 7C) . We then tested whether TGFb3 was still able to block PDGF-bb-stimulated migration of the cells. As shown in Fig. 7D , in control HDFs, PDGF-bb stimulation caused dramatically increased migration (panel b versus panel a), but failed to do so in the presence of TGFb3 (panel c). However, downregulation of the PKA-Ca by either shRNA-NO. 1 or shRNA-NO. 2 completely blocked antimotility signaling of TGFb3 (panels f and i versus panels e and h, respectively). Quantitation of the migration, Migration Index, was shown in Fig. 7E . Taken together, results of this study demonstrated that the ''TbII . TbI . R-Smads . PKA'' pathway mediates TGFb3's anti-motility signaling in HDFs, which represents a key cells traffic regulator during wound healing.
Discussion
The tumor suppressing effect of the TGFb family cytokines includes anti-proliferation and anti-motility. These two functions of TGFb also take an important part in the process of wound healing. A cell could only choose migration or proliferation, but not both, at a time. Immediately following the injury, the (B) Serum-starved HDFs were treated without or with TGFb3 or TGFb3 plus H89. Total cell lysates were subjected to immunoblotting analyses with indicated antibodies. (C) Serumstarved HDFs were subjected to colloidal gold migration assay, as previously described, in the absence or presence of PDGF-bb (bar 1 and 2) or PDGF-bb plus increasing concentrations of forskolin, an activator of PKA (bars 3 to 7). The effectiveness of forskolin (10.0 mM) on HDFs is indicated by causing an increased phosphorylation of CREB (insert image) in the cells. These experiments were repeated three times. *Statistically significant over the control, P,0.05.
anti-proliferation effect of TGFb3 from serum halts the proliferation mode of both epidermal and dermal cells and migration mode of only dermal cells at the wound edge, in order for epidermal keratinocytes to migrate toward the wound first (Sarret et al., 1992; Bandyopadhyay et al., 2006) . Following keratinocyte migration to re-epithelialize the wound, the dermal fibroblasts and dermal microvascular endothelial cells start to migrate into the wound bed. These findings provide a molecular mechanism for how keratinocyte migration occurs within hours, whereas the dermal cell migration is undetectable until 3-4 days later following the injury (reviewed by Singer and Clark, 1999) . While the anti-proliferation effect of TGFb has been studied in various cell culture models, the anti-motility signaling of TGFb has largely been overlooked over the years. In the current study, we took an advantage of the differential responses of epidermal keratinocytes and dermal fibroblasts to the anti-motility signal of TGFb3 to identify the pathway that mediates the anti-motility signal of TGFb3. As schematically shown in Fig. 8 , both antiproliferation and anti-motility signals of TGFb3 enter HDFs via the higher expression level of TbRII, whereas only the antiproliferation, but not anti-motility, signal of TGFb3 was able to enter keratinocytes due to a lower expression of TbRII. In HDFs, TGFbs uses the ''TbII . TbI . R-Smads . PKA'' pathway to execute its anti-motility signal.
Our finding of the R-Smads . PKA pathway to execute antimotility signal of TGFb3 is in line with several previous reports that the canonical R-Smad pathway can cross talk with the PKA pathway in cells. Zhang et al. showed that TGFb activates PKA via interaction between Smad2/3 and the regulatory subunit (R) of PKA, resulting in release of the catalytic subunit from the PKA holoenzyme in Mv1Lu cells (Zhang et al., 2004) . Chowdhury and colleagues reported that TGFb/PKA pathway is part of TGFb's 8 . A schematic representation of anti-motility versus anti-growth signaling by TGFb3 in two human skin cell types critical for wound healing. While TGFb3 blocks proliferation of both HDFs and HKCs, it selectively inhibits migration of HDFs, but not HKCs, due to 7 to 10 fold higher expression of TbRII (Bandyopadhyay et al., 2006) . TGFb3 uses TbRII/TbRI/ Smads 2/3 /Smad4/PKA pathway to transmit its anti-motility signal. The antiproliferation signaling by TGFb is beyond the scope of this study. The numbers in ''n 5'' are arbitrary to reflect the differences in TbR expression in fold between HDFs and HKCs.
tumor suppressing function that decreases the survival and inhibits metastasis of colon cancer cells (Chowdhury et al., 2011) . Moreover, consistent with our current finding, Giannouli and Kletsas reported that TGFb activates PKA in adult dermal fibroblasts (Giannouli and Kletsas, 2006) . Two groups also reported that PKA and CREB mediate TGFb-stimulated gene expression in the human keratinocyte cell line, HaCat, and other cell lines of epithelial origin (Schiller et al., 2003; Hayashida et al., 2006) . However, we detected weak CREB phosphorylation in response to TGFb3 stimulation and TGFb3 did not block migration of HKCs under these conditions. The discrepancy may be due to differences between the immortalized cell lines used by others and primary HKCs used in our study. It should be pointed out that, while the migration of HKCs is unaffected by TGFb3, HKCs, like HDFs, are equally sensitive to TGFb3's antiproliferation signal (Fig. 1B) . Therefore, the anti-motility signaling and anti-proliferation signaling of TGFb3 must take distinct signaling routes in the same cells. Our observation that the constitutively active TbRI-TD mutant was sufficient to convert HKCs to HDF-like cells toward the anti-motility signal of TGFb3 suggests that the ''degrees'' of TbRI activation (by the upstream TbRII) are different between HKCs and HDFs, which would determine transmission of either anti-proliferation signal alone or both anti-proliferation or anti-motility signals of TGFb3 into the cells.
Finally, how TGFb's anti-motility signal overrides PDGF-bb's pro-motility signal remains to be studied. For instance, where exactly the two opposite signals meet with each other, where they ''fight'' and TGFb's anti-motility effect wins over PDGF-bb's pro-motility effect, is the next important question for investigation. Results of our recent experiments pointed to the important focal adhesion protein, paxillin, as a center of this battlefield. It is known that extracellular signals regulate paxillin function by two ways: its phosphorylation status and its levels of expression. Changes in either of the two parameters could greatly affect cell morphology and motility (Turner, 2000) . While we observed that neither PDGF-bb nor TGFb3 significantly affect the protein levels of paxillin in HDFs, we found that PDGF-bb and TGFb3 regulate the serine and tyrosine phosphorylation of paxillin in opposite ways (A.H. and W.L., unpublished data). To functionally define the effects of the distinct phosphorylation levels and sites awaits further and technically challenging studies. In these studies, one would need to first deplete the endogenous wild type paxillin (permanently) and then to introduce various paxillin mutants on phosphorylation sites into these cells. We are currently testing if these opposite effects in paxillin phosphorylation are the reason by which TGFb3 executes its anti-motility effect over PDGF-bb's stimulatory effect.
Materials and Methods
Primary human neonatal HKCs and HDFs were purchased from Clonetics (San Diego, CA). HKCs were cultured in EpiLife medium with added human keratinocyte growth supplements (HKGS). HDFs were cultured in DMEM supplemented with 10% fetal bovine serum. The third or fourth passages of cells were used for experiments. rhPDGF-bb, rhTGFa, rhTGFb3, anti-phospho-CREB (Ser-133) antibody and anti-Smad4 antibody were purchased from R&D System (Minneapolis, MN). The sources of human TbR (I and II) and other Smad reagents, including TbRI-TD, TbRII-KD cDNAs, antibodies against TbRI/Alk5 and TbRII, anti-phospho-Smad2 (ser465/467) antibody and anti-Smad2/3 antibody were as previously described (Bandyopadhyay et al., 2006; Bandyopadhyay et al., 2011) . Anti-phospho-Smad2/3 or anti-phosphoSmad3 antibodies were from Abcam (Cambridge, MA). PD0325901 (PD901) was from Calbiochem (San Diego, CA). Human Phospho-Kinase Antibody Array (ARY 003) was purchased from R&D System. Anti-PKA Ca antibody, H-89 (dihydrochloride) and forskolin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and SigmaAldrich (St. Louis, MO), respectively. Rat type I collagen was purchased from BD Biosciences (San Jose, CA). Anti-b actin antibody and anti-GAPDH antibody were from Cell Signaling Technology, Inc. (Beverly, Massachusetts). XL-10 Gold Ultra competent cells (XL-10 Gold) (for lentiviral vectors) were from Stratagene (La Jolla, CA).
Immunostaining human skin with anti-TGFb antibodies
For immunostaining with anti-TGFb antibodies, we used a diamond cutter to make a highly visible circle around the tissue on the back of the slides with tissue specimen, washed and air-dried the slides. The tissue specimen on slides was fixed with 25 ml acetone for 5 min, washed with PBS, and blocked in 25 ml of the blocking reagent (1:10 dilution of normal goat serum, 0.05% Tween 20, 0.05 Triton X-100, and 1% BSA in PBS) for 60 min in a H 2 O humidified chamber. The slides were washed with PBS and incubated with a primary antibody for two hours. The slides were washed three times (7 min each) in PBS, incubated with FITCconjugated secondary antibody (added directly onto the tissue area) and covered to prevent exposing to light (for the rest of the procedures). Slides were subjected to final wash twice in PBS, air-dried and mounted. The results were analyzed under a microscope (1006 at 220˚C; TE-2000U Eclipse; Nikon) with application of green (FITC) fluorochrome in the absence of any imaging medium. The images were recorded in JPEG by an attached camera (TE-2000U; Nikon) using MetaMorph software (version-6.2rb; Universal Imaging). The detailed procedures are as previously described . This experiment was repeated with tissue specimen from multiple (.6) independent donors.
Cell migration assay and DNA synthesis assay
The colloidal gold migration assay was reported previously (Albrecht-Buehler, 1977) and modified and described in details by us (Li et al., 2004b) . Data from multiple independent experiments on HKCs or HDFs were calculated as Migration Index (MI), i.e. the percentage (%) of cell-migrated area over total areas under microscope, in response to corresponding stimulus/inhibitor over the baseline control (mean 6 s.d.), P,0.01-0.05. The [H 3 ]-thymidine incorporation assay to measure de novo DNA synthesis followed our previously published protocol (Bandyopadhyay et al., 2006) .
Lentiviral FG-12 and pRRLsinh-CMV systems
The lentivirus-derived FG-12 system for shRNA delivery, shRNA cloning and viral infection were carried out as previously described (Qin et al., 2003) and then modified (Guan et al., 2007) . The sense oligonucleotide shRNA sequence for TbRI, Smad2, Smad3, Smad4, and the PKA catalytic subunit (Ca) are as follows: Smad2, 59-GGACTGAGTACACCAAATA-39 and 59-GCAGAACTATCTCCT-ACTA-39, Smad3, 59-GCCTGGTCAAGAAACTCAA-39 and 59-GGTGCTC-CATCTCCTACTA-39, Smad4, 59-GGTGGAGAGAGTGAAACAT-39 and 59-GAATCCATATCACTACGAA-39. PKA-Ca, 59-GGGTCTCCATCAATGAGA-A-39 and 59-CCATCCAGATCTATGAGAA-39. The oligonucleotide shRNA sequence (59-GACCACAGACAAAGTTATA-39) for TbRI was previously reported (Bandyopadhyay et al., 2011) . The usage of the lentivirus-derived vector, pRRLsinh-CMV, for overexpressing genes of interest was as described in details (Li et al., 2004a) . Down-or up-regulation of genes was verified by Western blotting with corresponding antibodies (Bandyopadhyay et al., 2006) .
Human Phospho-Kinase Array assay
Passage 3 to 4 subconfluently-grown primary HDFs and HKCs in 15 cm tissue culture plates were serum-starved (with 0.2% FBS) overnight. The cells were treated with TGFb3 for 10 min under serum-free conditions. The cells were lysed (in commercially provided lysis buffer) and subjected to the Proteome Profiler Human Phospho-Kinase Array Kit (R&D Systems, Minneapolis, MN) strictly according to the manufacturer's instructions, including preparation of cell lysates (750 ml lysis buffer, scraped and centrifuged in a 1.5 ml Eppendorf tube at 13,000 g for 3 min at 4˚C), time and temperature for incubation with array membrane, washing, secondary antibodies and ECL. Results were verified by Western blotting experiments. Data were quantitated using an imager, ChemiDoc TM MP with Imagelab Version 4.0.1 software. For the phosphoarray's phosphoimager data, fold 5 +TGFb/2TGFb. For the Western blot data, fold 5 2TGFb/its own GAPDH 4 +TGFb/its own GAPDH.
Statistics
Data are presented as mean 6 standard deviation (s.d.). Statistical significance for comparisons was determined by the Student's two-tailed t-test. A p value equal or less than 0.05 was considered statistically significant .
